CURATIS N AG (CURN) fair value: what the stock is really worth
We calculate from audited financials what CURATIS N AG is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
- Compare price with fair valuebelow fair value = cheap, above = expensive
- Check the quality50 and up solid, 75 and up strong
- Watch it or check another stockalert when fair value or trend changes
At a glance
Below-average quality, and trading another 304% above our fair value of CHF 4.95.
As of Jul 18, 2026, the fair value of CURATIS N AG is CHF 4.95 per share against a price of CHF 20.00, so the fair value sits 75% below the price. A model estimate from reported figures, not an analyst target.
Fair value as of: Jul 18, 2026
From 1 valuation models · updated 54 days ago
Share price −1.5% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (CHF 7.39). The favourable scenario is already priced in.
- Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (CHF 3.70 to CHF 7.39) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range CHF 0.8960 – CHF 555.52 · fair‑value band CHF 3.70 – CHF 7.39 · the CHF 20.00 price screens above the CHF 4.95 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 18, 2026.
Analysis
CURATIS N AG (CURN) currently trades at CHF 20.00, while our model-based Fair Value estimate is CHF 4.95, implying the stock looks roughly 304.4% overvalued today. The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Over the trailing twelve months, CURATIS N AG generated revenue of CHF 10.8M at a net margin of −13.1%. Revenue grew 13.0% year over year. It earns a return on equity of −3.1%. The balance sheet holds a net cash position of CHF 1.9M. Fundamentals as of Jul 18, 2026
Scenario range: CHF 3.70 (bear) to CHF 7.39 (bull), the price of CHF 20.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 28% below its 52-week high and 99% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −75%, CURN screens richer than that median.
Fair Value models
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
All 1 models by family
Notify me when CURN reaches fair value
Put CURN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 62
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.
Full company description
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, nootropic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington's disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and C-FI-01 that is in phase I clinical trial for the treatment of fibrotic or inflammatory orphan or ultra-orphan diseases. The company was founded in 2002 and is based in Liestal, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CURATIS N AG reported revenue of CHF 10.8M in FY2025 versus CHF 0 in FY2021. Reported net income was −CHF 1.4M in FY2025.
CURN screens 304% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 613 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Context: sector, industry, market
- Is the Financials sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Valuation of the Switzerland market
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €135.85 | €106.48 | −22% |
| Takeda Pharmaceutical Company TAK | $18.45 | $11.64 | −37% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,899 | ₹989.50 | −48% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.76 | $15.33 | −58% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $73.56 | $104.88 | +43% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare CURATIS N AG with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is CURATIS N AG (CURN) overvalued or undervalued?
What is the fair value of CURN?
What is the quality score of CURN?
What is the price target for CURATIS N AG (CURN)?
What is the CURATIS N AG stock forecast for 2026?
What is the revenue of CURATIS N AG (CURN)?
What is the net profit margin of CURN?
What is the intrinsic value of CURATIS N AG (CURN)?
Is CURATIS N AG stock overvalued or undervalued in 2026?
Is fair value the same as the market price of CURN?
How much is CURATIS N AG worth?
What do the bullish and bearish scenarios say about CURN?
How solid is the balance sheet of CURATIS N AG (CURN)?
How far is CURN from its 52-week high?
Which stocks are comparable to CURATIS N AG?
Is CURATIS N AG stock attractive at the current price?
How is the fair value of CURN calculated?
Watch CURATIS N AG in the live analysis
One click puts CURATIS N AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.